Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | H002 |
Synonyms | |
Therapy Description |
H002 is a 4th-generation EGFR inhibitor, with activity against multiple EGFR mutations, which may lead lead to decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 5461). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
H002 | H-002|H 002 | EGFR Inhibitor 4th gen 16 | H002 is a 4th-generation EGFR inhibitor, with activity against multiple EGFR mutations, which may lead lead to decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 5461). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05519293 | Phase Ib/II | H002 | Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | Recruiting | USA | 0 |